Abstracts Archive - Page 1948 of 2425 - ACR Meeting Abstracts

Abstract Number: 1543 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in the Signs and Symptoms of Psoriatic Arthritis in DMARD-Naive Patients: Results from a Phase 3, Randomized, Controlled Trial
Alvin Wells¹, Adewale O. Adebajo², Jacob A. Aelion³, Paul Bird⁴, Alan Kivitz⁵, Frédéric Lioté⁶, Piercarlo Sarzi-Puttini⁷, ChiaChi Hu⁸, Randall M. Stevens⁸ and Christopher J. Edwards⁹, ¹Rheumatology & Immunotherapy Center, Franklin, WI, ²University of Sheffield, Sheffield, United Kingdom, ³West Tennessee Research Institute, Jackson, TN, ⁴Combined Rheumatology Practice, Kogarah, Australia, ⁵Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁶Hôpital Lariboisière & University Paris Diderot, Paris, France, ⁷Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ⁸Celgene Corporation, Warren, NJ, ⁹University Hospital Southampton, Southampton, United Kingdom
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis (PsA). PALACE…
Abstract Number: 1555 • 2014 ACR/ARHP Annual Meeting
An Indirect Comparison and Cost per Responder Analysis of Adalimumab, Methotrexate (MTX) and Apremilast in the Treatment of MTX-naïve Psoriatic Arthritis (PsA) Patients
Vibeke Strand¹, Jenny Griffith², Keith Betts³, Alan Friedman², James Signorovitch³ and Arijit Ganguli^2,4, ¹Stanford University, Palo Alto, CA, ²AbbVie, Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Apremilast (APR), a small molecule inhibitor of phospodiesterase 4 (PDE-4), was recently approved for treating PsA patients in the US. To date, there are…
Abstract Number: 1554 • 2014 ACR/ARHP Annual Meeting
Early and Sustained Modified Psarc Response in Psoriatic Arthritis Patients Treated with Ustekinumab: Results from 2 Phase 3 Studies
Iain B. McInnes¹, Christopher T. Ritchlin², Proton Rahman³, Lluís Puig Sanz⁴, Alice B. Gottlieb⁵, Shu Li⁶, Michael Song⁶, Bruce Randazzo⁶, Yuhua Wang⁶, Alan M. Mendelsohn⁷ and Arthur Kavanaugh⁸, ¹University of Glasgow, Glasgow, United Kingdom, ²Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵Tufts Medical Center, Boston, MA, ⁶Janssen Research & Development, LLC., Spring House, PA, ⁷Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁸University of California San Diego, La Jolla, CA
Background/Purpose: We have previously reported the efficacy and safety results of ustekinumab (UST), an IL-12/23 p40 inhibitor, in patients with active psoriatic arthritis (PsA) up…
Abstract Number: 1553 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Philip J. Mease¹, Roy Fleischmann², Owen Davies³, Tommi Nurminen⁴ and Désirée van der Heijde⁵, ¹Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ²Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim, Germany, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Early non-response to biologic therapy has been shown to be associated with a low probability of long-term response in rheumatoid arthritis1 and psoriasis2. However,…
Abstract Number: 1552 • 2014 ACR/ARHP Annual Meeting
Sustained Improvements in Workplace and Household Productivity and Social Participation with Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis
Arthur Kavanaugh¹, Dafna D. Gladman², Désirée van der Heijde³, Oana Purcaru⁴ and Philip J. Mease⁵, ¹University of California San Diego, La Jolla, CA, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴UCB Pharma, Brussels, Belgium, ⁵Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 The previous results…
Abstract Number: 1551 • 2014 ACR/ARHP Annual Meeting
Correlation of Individual HAQ Questions with Disease Activity Measures in Psoriatic Arthritis: Implications for Instrument Reduction
Denis Choquette¹, Carter Thorne², Majed Khraishi³, Isabelle Fortin⁴, Regan Arendse⁵, Andrew Chow⁶, John Kelsall⁷, Milton Baker⁸, Julie Vaillancourt⁹, John S. Sampalis⁹, Francois Nantel¹⁰, Allen J Lehman¹¹, Susan Otawa¹¹ and May Shawi¹⁰, ¹Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Nexus Clinical Research, St John's, NF, Canada, ⁴Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁷The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁸University of Victoria, Victoria, BC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose The Health Assessment Questionnaire (HAQ) is commonly used for assessing patient-reported functional status and disease activity in psoriatic arthritis (PsA). However, it has been…
Abstract Number: 1550 • 2014 ACR/ARHP Annual Meeting
Prevalence of Enthesitis and Dactylitis, Impact on Disease Severity and Evolution over 12 Months in Psa Patients Treated with Anti-TNF in a Real-World Setting
Proton Rahman¹, Denis Choquette², William Bensen³, Majed Khraishi⁴, Saeed Shaikh⁵, Regan Arendse⁶, Isabelle Fortin⁷, Andrew Chow⁸, Maqbool Sheriff⁹, Eliofotisti Psaradellis¹⁰, John S. Sampalis¹⁰, Susan Otawa¹¹, Francois Nantel¹², Allen J Lehman¹¹ and May Shawi¹², ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, ³Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁴Nexus Clinical Research, St John's, NF, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁸University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁹Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada
Background/Purpose Spondyloarthritis, including psoriatic arthritis (PsA), is characterized by inflammatory arthritis affecting axial and peripheral joints. It is commonly associated with extra-articular and peri-articular manifestations…
Abstract Number: 1549 • 2014 ACR/ARHP Annual Meeting
The Swedish Early Psoriatic Arhtritis (SWEPSA) Registry 5-Yeear Follow-up: Slow Radiographic Progression with Highest Scores in Male Feet and in Patients with Baseline X-Ray Abnormalities
Elke Theander¹, Tomas Husmark², Ulla Lindqvist³, Per T Larsson⁴, Annika Teleman⁵, Gerd-Marie Alenius⁶ and Mats Geijer⁷, ¹Skane University Hospital Malmö, Lund University, Malmö, Sweden, ²Rheumatology, Falu Hospital, Falun, Sweden, ³Rheumatology, Department of Medical Sciences, Rheumatology, University Hospital, Uppsala university, Uppsala, Sweden, ⁴Rheumatology, Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁵Rheumatology, Spenshult Rheumatological Hospital, Oskarström, Sweden, ⁶Rheumatology, Department of Public Health and Clinical Medicine, Rheumatology, Umeå University Hospital, Umeå, Sweden, ⁷Skåne University Hospital, Lund, Center for Medical Imaging and Physiology, Lund, Sweden
Background/Purpose: The aim of this study is to describe early X-ray findings in psoriatic arthritis (PsA) patients from the SwePsA registry using the Wassenberg score,…
Abstract Number: 1548 • 2014 ACR/ARHP Annual Meeting
Treatment Effect of Ustekinumab on Fatigue in Patients with Psoriatic Arthritis: Results from a Phase 3 Clinical Trial
Christopher T. Ritchlin¹, Proton Rahman², Lluís Puig Sanz³, Alice B. Gottlieb⁴, Arthur Kavanaugh⁵, Iain B. McInnes⁶, Shu Li⁷, Yuhua Wang⁷, Rita Ganguly⁸, Alan M. Mendelsohn⁹ and Chenglong Han⁸, ¹Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ³Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Tufts Medical Center, Boston, MA, ⁵University of California San Diego, La Jolla, CA, ⁶Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁷Janssen Research & Development, LLC., Spring House, PA, ⁸Janssen Global Services, LLC., Malvern, PA, ⁹Immunology, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: To assess the treatment effect of ustekinumab on fatigue using data from PSUMMIT 2. Methods: Adult patients with active psoriatic arthritis (PsA) despite DMARD…
Abstract Number: 1547 • 2014 ACR/ARHP Annual Meeting
Endocrine Co-Morbidities in Patients with Psoriatic Arthritis: A Population-Based Study
Devy Zisman^1,2, Ron Ilan Ashkenazi³, Haim Bitterman^4,5, Guy Shallom⁶, Ilan Feldhamer⁶, Idit Lavi⁷, Sari Greenberg-Dotan⁶ and Arnon-Dov Cohen⁶, ¹Dept of Internal Medicine, Carmel Medical Center, Haifa, Israel, ²The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel, ³Carmel Medical Center, Haifa, Israel, ⁴Chief Physician's Office, Clalit Health Services, Haifa, Israel, ⁵Technion, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel, ⁶Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel, ⁷Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel
Background/Purpose: Co-morbidities associated with psoriatic arthritis (PsA) include cardiovascular, ophthalmic and gastrointestinal diseases. The aim of the study was to investigate endocrine co-morbidities in patients…
Abstract Number: 1546 • 2014 ACR/ARHP Annual Meeting
Risk of Non Melanoma Skin Cancer Among Medicare Psoriasis/Psoriasis Arthritis Patients
Huifeng Yun¹, Kevin L. Winthrop², Lang Chen³, Wilson Smith⁴, Benjamin Chan⁵, Fenglong Xie⁶, Allison Taylor⁴, Ronac Mamtani⁷, Frank I Scott⁷, James D. Lewis⁸ and Jeffrey R. Curtis⁹, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Oregon Health and Science University, Portland, OR, ⁶Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Many systemic treatments for psoriatic arthritis and psoriasis (PsA/PsO) are immune-modulating, which may increase the risk of non-melanoma skin cancer (NMSC). However, the comparative…
Abstract Number: 1562 • 2014 ACR/ARHP Annual Meeting
Psoriasis Longitudinal Assessment and Registry: Global Update upon Full Enrollment
Bruce Strober¹, Alan Menter², Craig Leonardi³, Lyn Guenther⁴, Kavitha Goyal⁵, Wayne Langholff⁶, Steve Calabro⁵ and Steve Fakharzadeh⁷, ¹University of Connecticut Heatlh Center, Farmington, CT, ²Baylor Research Institute, Dallas, TX, ³Central Dermatology, St. Louis, MO, ⁴The Guenther Dermatology Research Centre, London, ON, Canada, ⁵Janssen Services, LLC, Horsham, PA, ⁶Janssen Research and Development, LLC, Spring House, PA, ⁷Janssen Services, LLC, Spring House, PA
Background/Purpose To report the baseline demographics and clinical characteristics of participants enrolled in the Psoriasis Longtitudinal Assessment and Registry (PSOLAR) study. Methods PSOLAR is a…
Abstract Number: 1561 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, and the Impact of Baseline Weight and BMI on ACR20 and HAQ-DI Response: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
Georg A. Schett¹, Philip J. Mease², Dafna D. Gladman³, Arthur Kavanaugh⁴, Adewale O. Adebajo⁵, Juan J. Gomez-Reino⁶, Jurgen Wollenhaupt⁷, Maurizio Cutolo⁸, Eric Lespessailles⁹, ChiaChi Hu¹⁰, Randall M. Stevens¹⁰, Christopher J. Edwards¹¹ and Charles A. Birbara¹², ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Swedish Medical Center and University of Washington, Seattle, WA, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of California San Diego, La Jolla, CA, ⁵University of Sheffield, Sheffield, United Kingdom, ⁶Rheumatology, Hospital Clinico Universitario, Santiago, Spain, ⁷Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ⁸Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁹University of Orléans, Orléans, France, ¹⁰Celgene Corporation, Warren, NJ, ¹¹University Hospital Southampton, Southampton, United Kingdom, ¹²University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR) is a phosphodiesterase 4 inhibitor that helps to regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis…
Abstract Number: 1560 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Factor Status Is a Predictor of Osteoporosis in Patients with Psoriatic Arthritis
Frank Behrens^1,2, Michaela Koehm^2,3, Eva C. Scharbatke⁴, Bianca Wittig⁵, Marc Schmalzing⁴, Holger Gnann⁶, H M Lorenz⁷, Diamant Thaci⁸ and Harald Burkhardt^1,9, ¹Rheumatology, Goethe-University Frankfurt, Frankfurt, Germany, ²Clinical Research, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ³Rheumatology, Goethe-University Frankfurt, Frankfurt/Main, Germany, ⁴Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ⁵Abbvie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁶Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbH, München, Germany, ⁷University Hospital Heidelberg, Heidelberg, Germany, ⁸Comprehensive Center of Inflammation Medicine, University Hospital Schleswig Holstein Campus Luebeck, Lübeck, Germany, ⁹Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany
Background/Purpose Osteoporosis is an important comorbidity in patients with rheumatic diseases, but risk factors for osteoporosis in Psoriatic Arthritis (PsA) patients have not been explored. …
Abstract Number: 1559 • 2014 ACR/ARHP Annual Meeting
Long Term Improvements in Physical Function Are Associated with Improvements in Dactylitis, Enthesitis, Tender and Swollen Joint Counts, and Psoriasis Skin Involvement: Results from a Phase 3 Study of Ustekinumab in Psoriatic Arthritis Patients
Arthur Kavanaugh¹, Lluís Puig Sanz², Alice B. Gottlieb³, Christopher T. Ritchlin⁴, Shu Li⁵, Yin You⁵, Alan M. Mendelsohn⁶, Michael Song⁵, Proton Rahman⁷ and Iain B. McInnes⁸, ¹University of California San Diego, La Jolla, CA, ²Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³Tufts Medical Center, Boston, MA, ⁴Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Janssen Research & Development, LLC., Spring House, PA, ⁶Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁷Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁸Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: To evaluate the association of improvements in tender and swollen joint counts (TJC, SJC), psoriasis skin involvement, and dactylitis/enthesitis (in patients affected at baseline)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].